BCG-unresponsive bladder cancer
New options for non-muscle invasive bladder cancer after BCG fails.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 1, 7, 12, 9, 12.
New guidelines and consensus this year
All papers from the last 12 months
128 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapyOncoimmunology2026 Dec 31PMID 42771543Review
- Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United StatesJ Med Econ2026 DecPMID 42012856
- Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapyJ Med Econ2026 DecPMID 41780023
- Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancerFuture Sci OA2026 DecPMID 41661092Review
- Strategic sequencing of bladder-sparing therapies in the management of BCG-unresponsive non-muscle invasive bladder cancerAnn Med2026 DecPMID 41508603
- Artificial intelligence for predicting BCG response in non-muscle-invasive bladder cancer: a systematic reviewBJU Int2026 NovPMID 42605566Systematic review
- A Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Nonmuscle-Invasive Bacillus Calmette-Guérin-Unresponsive Urothelial Carcinoma of the BladderJ Urol2026 NovPMID 42467648
- Durable Responses and Cystectomy Avoidance With Interleukin-15 Receptor Agonist NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer With Carcinoma In Situ ± Papillary DiseaseJ Urol2026 NovPMID 42406609
- Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategiesNat Rev Urol2026 Oct 15PMID 42881230Review
- Contemporary Oncological and Patient-reported Outcomes of Intravesical Gemcitabine/Docetaxel in BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Multi-institutional Prospective Cohort StudyEur Urol Focus2026 Oct 13PMID 42869744
More urology trends
All specialties →PSMA PET in prostate cancer
PSMA PET imaging for staging and recurrence of prostate cancer.
Key point: PSMA-PET/CT is recommended only when PSA exceeds 0.2 μg/L, reporting should follow PSMA-RADS, and it is preferred over lymph-node dissection for staging.
Male infertility
Male infertility and trends in semen quality.
Key point: Male infertility management should be couple-centered, integrating the female partner's reproductive timeline to avoid preventable delays in effective therapy.
Robotic partial nephrectomy
Robot-assisted partial nephrectomy for kidney tumours.
Focal therapy for prostate cancer
Treating only the tumour area within the prostate.
Beta-3 agonists for overactive bladder
Mirabegron and vibegron for overactive bladder.
Key point: Vibegron appears to rank more favourably for urgency, urgency incontinence and maximum voided volume, while mirabegron ranks more favourably for 24-hour frequency.
Preventing recurrent UTIs
Vaccines and non-antibiotic prevention of recurrent urinary tract infections.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"BCG-unresponsive"[tiab] OR ("non-muscle invasive bladder cancer"[tiab] AND (nadofaragene[tiab] OR "TAR-200"[tiab] OR cretostimogene[tiab] OR "N-803"[tiab]))Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.